Neuphoria Therapeutics Inc. (NEUP)
2025-03-31 | 2024-12-31 | |||
|---|---|---|---|---|
| Revenue | 15,000,000 | 662,715 | ||
| Research and development | 1,616,011 | 1,737,039 | ||
| General and administrative | 1,406,796 | 2,629,187 | ||
| Total operating expenses | 3,022,807 | 4,366,226 | ||
| Income (loss) from operations | 11,977,193 | -3,703,511 | ||
| Interest income, net | 12,741 | 30,615 | ||
| Gain (loss) on foreign currency transactions | 172,946 | 629,501 | ||
| Gain (loss) on fair value adjustments | -976,678 | 805,422 | ||
| Research and development incentive award | 5,227 | -306,233 | ||
| Total other income (loss) | -796,218 | 1,771,771 | ||
| Income (loss) before income tax expense | 11,180,975 | -1,931,740 | ||
| Income tax benefit (expense) | -81,186 | 11,609 | ||
| Net income (loss) | 11,262,161 | -1,943,349 | ||
| Unrealized loss on foreign currency translation | -195,818 | -1,288,433 | ||
| Total other comprehensive loss | -195,818 | -1,288,433 | ||
| Comprehensive income (loss) | 11,066,343 | -3,231,782 | ||
| Basic eps | 6.55 | -1.23 | ||
| Diluted eps | 6.55 | -1.23 | ||
| Basic average shares | 1,719,073 | 1,575,244 | ||
| Diluted average shares | 1,719,073 | 1,575,244 | ||